Patent · US Active

Use of anti-CS1 antibodies for treatment of rare lymphomas

US8603477B2 · kind B2 · utility

14Cited by

10References

30Claims

0Family size

Assignees

ABBVIE BIOTHERAPEUTICS INC. · US
The Cleveland Clinic Foundation · US

Inventors

Daniel Afar · Santa Monica, US
Eric Hsi · Warrensville Heights, US

Key dates

Filing date	Oct 29, 2009
Grant date	Dec 10, 2013
Priority date	—
Expiry date	Feb 24, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/505
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Uses of anti-CS1 antibodies, alone or in combination with other agents, for the treatment of rare lymphomas, such as NK lymphomas, NK/T-cell lymphomas, and angioimmunoblastic lymphomas.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.